SCIENTIFIC PROGRAM

FRIDAY, JUNE 26, 2026

Panel: Therapeutic Implications of Molecular Heterogeneity
Introduction: MIB Agents Junior Advisory Member
Moderator: Anand Patel, MD, PhD | St. Jude Children's Research Hospital

Weisong Zhao, MD, PhD candidate | Shanghai Bone Tumor Institute, Shanghai General Hospital
Deciphering Complex Oncogenic Amplicons in Osteosarcoma

Ianthe van Belzen, PhD | EMBL-EBI (European Bioinformatics Institute)
Unravelling the phenotypic and clinical impact of complex genomic rearrangements in osteosarcoma

Yanding Zhao, PhD | Mohamed bin Zayed University of Artificial Intelligence (MBZUAI)
Distinct patterns of chromosomal instability fuel osteosarcoma progression and influence patient outcomes

Andrew Clugston, PhD | University of California, San Francisco
Identifying tumor-specific vulnerabilities by mapping oncogenic structural variation in osteosarcoma

Corey Weistuch, PhD | Memorial Sloan Kettering Cancer Center
Implementing personalized, adaptive therapies in osteosarcoma

Amy LeBlanc, DVM, DACVIM | NIH/National Cancer Institute
Canine osteosarcoma multiomic profiling provides new insights and therapeutic opportunities for dogs and humans

Panel: From Crosstalk to Targets: Exploiting the Tumor Microenvironment
Introduction: MIB Agents Junior Advisory Member
Moderator: Dan Regan, DVM, PhD | Flint Animal Cancer Center, Colorado State University

Amy Gross, MS | Nationwide Children's Hospital
Metastasis-Initiating Osteosarcoma Cells Shape Lung Microenvironment Through Paracrine Signaling

Rebecca Makii, MS, DVM | Colorado State University
Understanding the metastatic osteosarcoma tumor microenvironment using cross-species spatial transcriptomics

Fatemeh Yazarlou, PhD | Nationwide Children's Hospital
Cell-type–resolved mapping of tumor-specific kinase networks in the osteosarcoma metastatic niche predicts effective Tyrosine kinase inhibitors (TKIs) therapy

Rebecca Nance-Richey, PhD | University of Florida
Spatial Transcriptomic Sequencing of Canine Osteosarcoma Reveals Immune Niches in the Tumor Microenvironment

Yogesh Budhathoki, PhD Candidate | Nationwide Children's Hospital
Integrative Single-cell and Spatial Transcriptomic Analysis of Osteosarcoma Reveals Conserved and Distinct Ecosystems Across Sites and Species

Draft as of 3.17.26
CONFIDENTIAL- Please do not circulate

SCIENTIFIC PROGRAM

Update: Break Through Cancer - Defying Osteosarcoma Team Lab
Katie Janeway, MD, MMSc | Dana-Farber Cancer Institute

OutSmarting Osteosarcoma 2026 Awards Presentation
Moderators: Christina Ip-Toma | MIB Agents and Matteo Trucco, MD | Cleveland Clinic

TBD

Panel: Evolving Strategies for Local Control
Introduction: MIB Agents Junior Advisory Member
Moderator: Thomas Scharschmidt, MD | Nationwide Children's Hospital

Anna R. Cooper, MD, MPH | Montefiore Einstein
Functional Outcomes After Upfront Surgery for Osteosarcoma: A Pilot Study

Daniel Ebner, MD, MPH | Mayo Clinic
High LET Radiotherapy for Osteosarcoma

Theresa Busch, PhD | University of Pennsylvania
FLASH Ultra-high Dose Rate Radiotherapy in the Treatment of Osteosarcoma

Aleyna La Croix, MS, PhD Student | Dartmouth College
MXene-Integrated Scaffolds for Localized Tumor Treating Field Delivery in Osteosarcoma

Erin S. Murphy, MD | Cleveland Clinic
Sarcoma SBRT Task Force

SCIENTIFIC PROGRAM

Panel: Expanding Immunotherapy Approaches in Osteosarcoma
Introduction: MIB Agents Junior Advisory Member
Moderator: Nancy Gordon, MD | The University of Texas MD Anderson Cancer Center

Joseph Skeate, PhD | University of Minnesota
Next generation dual-CAR γδ T cells for the treatment of pediatric osteosarcoma

Ali Cihan, PhD | Memorial Sloan Kettering Cancer Center
Development of EPHA2 CAR T Cell Therapy for Pediatric Osteosarcoma

William Kisseberth, DVM, PhD | The Ohio State University
Phase I evaluation of adjuvant cell therapy with TGF beta-resistant NK cells in dogs with osteosarcoma

Jeffrey Bryan, DVM, MS, PhD | University of Missouri
Improving Outcomes in Osteosarcoma: Vaccine-enhanced Adoptive Cell Therapy After Short-Course Chemotherapy in a Naturally Occurring Canine Model

Julie Tomolonis, MD, PhD | Nationwide Children's Hospital
Dual targeting of osteosarcoma and stromal microenvironment using FAP-directed immunotherapeutics

SATURDAY, JUNE 27, 2026

Panel: Molecular Pathways and Therapeutic Vulnerabilities
Introduction: MIB Agents Junior Advisory Member
Moderator: Ryan D. Roberts, MD, PhD | Nationwide Children's Hospital/The Ohio State University

Pankita H. Pandya, PhD | Indiana University School of Medicine
BET Bromodomain Targeting Induces TXNIP, DNA Damage, and Potentiates Salvage Chemotherapy in Preclinical Models of Osteosarcoma

Emily Seiden, PhD | University of Michigan
MYC Modulation Alters Metastasis in High-Risk Osteosarcoma

Janeala Morsby, PhD | St. Jude Children's Research Hospital
Potentiating Cohesin Collapse With PARP Plus ATM Inhibition In Pediatric Osteosarcoma

Alexander Davies, DVM, PhD | Knight Cancer Institute, Oregon Health and Science University
Decoding niche organization patterns and signaling dynamics that underlie osteosarcoma cell fates

H. David Ulmert, MD, PhD | University of California, Los Angeles
Developing LRRC15-Targeted Radiotheranostics to Ablate Aggressive Osteosarcoma and Reprogram TGFβ-Driven Immunoresistance

Draft as of 3.17.26

SCIENTIFIC PROGRAM

Panel: Addressing Chemoresistance in Osteosarcoma
Introduction: MIB Agents Junior Advisory Member
Moderator: Livia Garzia, PhD | McGill University

Surabhi Menon, MD | Memorial Sloan Kettering Cancer Center/ New York Presbyterian Weill Cornell
Proteo-genomic profiling of chemotherapy persistence in Osteosarcoma PDX models

Zachary Burke, MD | Cleveland Clinic
Evolving toward precision oncology: Leveraging collateral drug responses for personalized second-line osteosarcoma treatment

Laurie Graves, MD | Duke University
Eco-Evolutionary Strategies for Extinction-Based Therapy in Osteosarcoma

Aafrin Pettiwala, PhD | University of California, San Francisco
Tracking tumor clonal dynamics in response to chemotherapy in metastatic osteosarcoma using molecular barcoding

Ram Rao, MD, PhD | Seattle Children's Research Institute
Extracellular Matrix Density Mediates Osteosarcoma Phenotype

Panel: Novel Therapeutic Modalities and Delivery Strategies
Introduction: MIB Agents Junior Advisory Member
Moderator: Richard Gorlick, MD | The University of Texas MD Anderson Cancer Center

Jay Sarthy, MD, PhD | Seattle Children's Research Institute
Epigenetic Targeting of Translation in Osteosarcoma

Jonathan Gill, MD | The University of Texas MD Anderson Cancer Center
Development of Antibody-Drug Conjugates in Osteosarcoma

Sagar Bhattacharya, PhD | University of California, San Francisco
De novo design of radium-binding proteins

Iman Mevaa, PhD Candidate |Purdue University
MicroRNA for Major Impact: Ligand-Mediated Delivery of Tumor-Suppressive miRNA-34a to Treat Osteosarcoma

Masahiro Hitomi, MD, PhD | Cleveland Clinic
Enhancing osteosarcoma immunotargeting efficacy by combination therapy

Draft as of 3.17.26
CONFIDENTIAL- Please do not circulate

SCIENTIFIC PROGRAM

Panel: Patient Panel
Introduction: MIB Agents Junior Advisory Member
Moderator: Matthew Dietz, DO, MSEd | Primary Children's Hospital, University of Utah
MIB Junior Advisory Board Panelists

Update: CURE-OS - Collaborative Understanding of the Range and Evolution of Osteosarcoma Single-cells

Jovana Pavisic, MD | Memorial Sloan Kettering Cancer Center
Overview, Background, Goals

Dan Regan, DVM, PhD | Colorado State University
Decoding the Osteosarcoma Tumor Microenvironment: A Review and Outlook for Clinical Translation

Anand Patel, MD, PhD | St. Jude Children's Research Hospital
A roadmap for osteosarcoma: intratumoral heterogeneity

Corey Weistuch, PhD | Memorial Sloan Kettering Cancer Center
Next Steps

Panel: Clinical Trials
Introduction: MIB Agents Junior Advisory Member
Moderator: Sarah Whittle, MD | St. Jude Children's Research Hospital

Amy E. Armstrong, MD | Washington University in St. Louis
Open-label, cohort-sequential dose-escalation and dose-confirmation Phase 1/2 clinical trial to evaluate the safety and efficacy of domatinostat in combination with sirolimus in adolescents and adults with relapsed, refractory sarcoma and osteosarcoma

Michelle Choe, MD | Fred Hutch Cancer Center/Seattle Children's Hospital
FIERCe: FOLR1 Immune Effector Cell Therapy against Advanced Osteosarcoma

Noah Federman, MD | University of California, Los Angeles
A Phase 1/2 Study to Evaluate LNTH-2403, a LRRC15-targeted 177Lutetium-labeled Monoclonal Antibody, in Participants With Relapsed / Refractory Osteosarcoma: A trial in progress

Alice Lee, MD | Children's Hospital at Montefiore
DFMO Maintenance for patients with relapsed/refractory Ewing sarcoma or Osteosarcoma

Filemon Dela Cruz, MD | Memorial Sloan Kettering Cancer Center
OstEvo: A Strategy-Based Clinical Trial Advancing New Treatment Strategies for Metastatic and Relapsed Osteosarcoma